Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses the rationale for combining agents like dabrafenib with trametinib or binimetinib with encorafenib for patients with melanoma.<br />
Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses the rationale for combining agents like dabrafenib (Tafinlar) with trametinib (Mekinist) or binimetinib (Mektovi) with encorafenib (Braftovi) for patients with melanoma.
We’ve known for a number of years that mutatedBRAFis a bonafide therapeutic target for this patient population, Flaherty explains. Approximately 45% of patients with melanoma have activating mutations in BRAF. Around 2009, vemurafenib (Zelboraf) and dabrafenib came along and proved thatBRAFmutations were therapeutic targets. Within a few years, these drugs were FDA-approved for this patient population.
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More